Press Releases

2010 | 2009 | 2008 | 2007 | 2006
Keyword Search
 
DateTitle
09/09/10Depomed to Present at the Rodman & Renshaw 12th Annual Healthcare Conference
08/11/10Depomed Reaches SPA Agreement With FDA for Phase 3 Hot Flash Trial
08/05/10Depomed Licenses GLUMETZA(R) Data and Acuform(R) Technology
08/05/10Depomed Reports Second Quarter 2010 Financial Results
08/03/10Depomed Receives Confirmation from Pfizer That No Infringement Suit to be Filed on DM-1796 NDA
07/29/10Depomed to Announce Second Quarter 2010 Financial Results on August 5, 2010
06/28/10Depomed Announces Receipt of a $10 Million Milestone Payment for DM-1796
06/28/10New Clinical Study Shows Patients With Type 2 Diabetes May Be Able to Tolerate Higher Doses of Metformin Using GLUMETZA
06/07/10Depomed Announces Acceptance of New Drug Application for Investigational Postherpetic Neuralgia Treatment DM-1796
05/04/10Depomed to Present at the 9th Annual JMP Securities Research Conference
04/29/10Depomed to Present at the Deutsche Bank 35th Annual Health Care Conference
04/29/10Depomed Reports First Quarter 2010 Financial Results
04/22/10Depomed to Announce First Quarter 2010 Financial Results on April 29, 2010
03/31/10Depomed to Present at the BioCentury and Thomson Reuters Future Leaders In The Biotech Industry Conference
03/30/10Depomed Announces Submission of New Drug Application for Investigational Postherpetic Neuralgia Treatment DM-1796
03/08/10Depomed to Present at the ROTH 22nd Annual OC Growth Stock Conference
03/04/10Depomed Reports Fourth Quarter and Year-End 2009 Financial Results
03/02/10Depomed to Present at the Cowen and Company 30th Annual Health Care Conference
02/25/10Depomed to Announce Fourth Quarter and Year-End 2009 Financial Results on March 4, 2010
02/18/10Depomed Comments on DM-1796 Pre-NDA Meeting and Horizant(R) Complete Response Letter
02/02/10Depomed to Present at the 12th Annual BIO CEO & Investor Conference
02/01/10Depomed Announces Allowance of U.S. Patent Covering Gastric Retentive Gabapentin Dosage Forms
01/21/10Depomed Announces Receipt of $500,000 Milestone Payment from Covidien for the Development of a Second Formulation
01/19/10Depomed Comments on FDA Guidance and Plans for One Additional Phase 3 Clinical Trial Evaluating Non-Hormonal Therapy for Menopausal Hot Flashes